Login / Signup

Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: A randomized, double-blind, crossover, euglycaemic glucose clamp study.

Ulrike HoevelmannYaron RaiterAnoop ChullikanaMark LiuCharles DonnellyTracey LawrenceNilanjan SenguptaGopu ClGopinath RangannaAbhijit Barve
Published in: Diabetes, obesity & metabolism (2021)
MYL-1601D showed BE to Ref-InsAsp-US and Ref-InsAsp-EU with a comparable safety profile.
Keyphrases
  • double blind
  • placebo controlled
  • type diabetes
  • clinical trial
  • open label
  • study protocol
  • blood glucose
  • randomized controlled trial
  • metabolic syndrome
  • glycemic control
  • phase iii
  • phase ii
  • weight loss
  • skeletal muscle